INNOVATIONS IN OBESITY TREATMENT – GLP – 1 PHARMACOTHERAPY AND BARIATRIC SURGERY
Abstract
Background: Obesity is a growing global health challenge requiring effective, long - term treatment strategies. This paper focus on two leading innovations: GLP - 1 receptor agonists and bariatric surgery. GLP - 1 - based pharmacotherapy, including agents like semaglutide and tirzepatide, has shown impressive weight loss outcomes by regulating appetite and glucose metabolism. Meanwhile, bariatric procedures such as sleeve gastrectomy and gastric bypass remain the most effective interventions for severe obesity, offering sustained weight reduction and improvement of metabolic comorbidities. By comparing the efficiency, safety, and indications of both approaches, this paper show how pharmacological and surgical treatments can work synergistically to improve patient outcomes in obesity management.
Aim: The aim of this article is to highlight the challenges involved in treating obesity especially using GLP - 1 receptor agonists and bariatric surgery.
Methods: A review of scientific articles published on ResearchGate and PubMed from 2013 to 2025.
Results: Both GLP - 1 receptor agonists and metabolic surgery were found to be effective in reducing body weight and improving metabolic health in obese patients. Treatment with GLP - 1 analogs such as liraglutide or semaglutide led to moderate weight loss, typically between 5–15% of initial body weight. These medications also improved blood sugar control and lipid levels. Metabolic surgery, including sleeve gastrectomy and gastric bypass, resulted in greater weight reduction - often 25 - 35%, and more significant improvement in conditions like type 2 diabetes and hypertension. Interestingly, GLP - 1 levels tend to rise after surgery, suggesting that hormonal changes may partly explain the effectiveness of surgical interventions. In summary, both approaches show clear benefits, with surgery providing stronger effects, while GLP - 1 therapy offers a less invasive option.
Conclusion: GLP - 1 receptor agonists and metabolic surgery are methods to cure obesity and both of these methods are effective. GLP - 1 therapies offer a non - invasive option with metabolic benefits, while surgery provides greater and more sustained weight loss. The rise in GLP - 1 levels after surgery suggests shared mechanisms. Choosing the right approach should be based on individual patient needs and clinical factors.
References
World Health Organization. (n.d.). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Wąsowski, M., Walicka, M., & Marcinowska-Suchowierska, E. (2013). Obesity – definition, epidemiology, pathogenesis. Postępy Nauk Medycznych, 4, 301–306.
Potter, A. W., Chin, G. C., Looney, D. P., & Friedl, K. E. (2025). Defining overweight and obesity by percent body fat instead of body mass index. The Journal of Clinical Endocrinology & Metabolism, 110(4), e1103–e1107. https://doi.org/10.1210/clinem/dgae341
Orłowski, W., Merkisz, K., Zdun, S., Walczak, K., Walczak, P., Nemeczek, S., et al. (2023). GLP-1 agonists in treatment of obesity. Journal of Education, Health and Sport, 13(2), 229–234. https://apcz.umk.pl/JEHS/article/view/41396
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020). Benefits and risks of bariatric surgery in adults: A review. JAMA, 324(9), 879–887. https://doi.org/10.1001/jama.2020.12567
Urva, S., Coskun, T., Loghin, C., et al. (2020). The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism, 22(10), 1886–1891. https://doi.org/10.1111/dom.14110
Biondi, F., & Madonna, R. (2025). The potential role of GLP1-RAs against anticancer-drug cardiotoxicity: A scoping review. Journal of Clinical Medicine, 14(8), 2705. https://doi.org/10.3390/jcm14082705
Kadowaki, T., Isendahl, J., Sangnier, M., Pierk, J., Ayyoub, S., David, N., et al. (2024). Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: A systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes, Obesity and Metabolism, 26(6), 1289–1302. https://doi.org/10.1111/dom.15544
Cai, X., Gao, X., Yang, W., Chen, Y., Zhang, S., Han, X., et al. (2022). The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese patients without diabetes: A systematic review and meta-analysis of 24 RCTs. Diabetes Therapy, 13(4), 1167–1183. https://doi.org/10.1007/s13300-022-01235-y
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). Efficacy and safety of glucagon like peptide 1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials. Annals of Internal Medicine, 178(2), 199–217. https://doi.org/10.7326/ANNALS2401590
Tan, B., Pan, X. H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., et al. (2023). Efficacy and safety of tirzepatide for treatment of overweight or obesity: A systematic review and meta-analysis. International Journal of Obesity, 47(8), 677–685. https://doi.org/10.1038/s41366-023-01321-5
Singh, A., et al. (2025). Effect of glucagon like peptide 1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 164, 156113. https://doi.org/10.1016/j.metabol.2024.156113
Sun, F., Chai, S., Yu, K., Quan, X., Yang, Z., Wu, S., et al. (2015). Gastrointestinal adverse events of glucagon like peptide 1 receptor agonists in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Technology & Therapeutics, 17(1), 35–42. https://doi.org/10.1089/dia.2014.0188
Frias, J. P., Nauck, M. A., Van, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2035389
Harmel, P., et al. (2023). Efficacy and safety of retatrutide, a triple receptor agonist, in adults with obesity: A phase 2 trial. The Lancet Diabetes & Endocrinology, 11(5), 334–345. https://doi.org/10.1016/S2589-7500(23)00103-1
Lee, Y., Doumouras, A. G., Yu, J., et al. (2019). Roux-en-Y gastric bypass versus sleeve gastrectomy for obese patients: A meta-analysis. Surgery, 165(4), 795–803. https://doi.org/10.1016/j.surg.2018.11.020
Chang, S. H., Stoll, C. R., Song, J., et al. (2014). The effectiveness and risks of bariatric surgery: An updated systematic review and meta-analysis, 2003–2012. JAMA Surgery, 149(3), 275–287. https://doi.org/10.1001/jamasurg.2013.3654
Zhao, Z., Jiao, J., Wang, Z., et al. (2020). Long-term outcomes of sleeve gastrectomy versus Roux-en-Y gastric bypass for morbid obesity: A meta-analysis of randomized controlled trials. Obesity Surgery, 30(1), 224–233. https://doi.org/10.1007/s11695-019-04294-z
English, W. J., DeMaria, E. J., Hutter, M. M., et al. (2018). Bariatric surgery procedural volume in the United States, 2011–2016. Surgery, 163(5), 1150–1156. https://doi.org/10.1016/j.surg.2017.12.006
Li, J. F., Lai, D. D., Lin, Z. H., Jiang, T. Y., Zhang, A. M., & Dai, J. F. (2014). Comparison of the long-term results of Roux-en-Y gastric bypass and sleeve gastrectomy for morbid obesity: A systematic review and meta-analysis of randomized and nonrandomized trials. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques, 24(1), 1–11. https://doi.org/10.1097/SLE.0000000000000041
Amundsen, T., Strømmen, M., & Martins, C. (2016). Suboptimal weight loss and weight regain after gastric bypass surgery—Postoperative status of energy intake, eating behavior, physical activity, and psychometrics. Obesity Surgery, 27(5), 1316–1323. https://doi.org/10.1007/s11695-016-2475-7
Pech, N., Meyer, F., Lippert, H., Manger, T., & Stroh, C. (2012). Complications and nutrient deficiencies two years after sleeve gastrectomy. BMC Surgery, 12, 13. https://doi.org/10.1186/1471-2482-12-13
Sasaki, A., Nitta, H., Otsuka, K., Umemura, A., Baba, S., Obuchi, T., & Wakabayashi, G. (2014). Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Frontiers in Endocrinology, 5, 164. https://doi.org/10.3389/fendo.2014.00164
Zhou, H., Luo, P., Li, P., Wang, G., Yi, X., Fu, Z., Sun, X., Cui, B., Zhu, L., & Zhu, S. (2022). Bariatric surgery improves nonalcoholic fatty liver disease: Systematic review and meta-analysis. Obesity Surgery, 32(6), 1872–1883. https://doi.org/10.1007/s11695-022-06011-1
Elsaid, M. I., Li, Y., Bridges, J. F. P., Brock, G., Minacapelli, C. D., & Rustgi, V. K. (2022). Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Network Open, 5(10), e2235003. https://doi.org/10.1001/jamanetworkopen.2022.35003
Courcoulas, A. P., Gallagher, J. W., Neiberg, R. H., Strohbehn, G. W., Wolfe, B., Twells, L., et al. (2020). Bariatric surgery vs medical management in severely obese adults. JAMA Surgery, 155(3), e195925. https://doi.org/10.1001/jamasurg.2019.5925
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Wharton, S., Connery, L., & Aronne, L. J. (2023). Practical considerations for initiating tirzepatide in clinical practice for treatment of obesity. Obesity, 31(4), 733–742. https://doi.org/10.1002/oby.23698
Srivastava, G., & Apovian, C. M. (2018). Current pharmacotherapy for obesity. Nature Reviews Endocrinology, 14(1), 12–24. https://doi.org/10.1038/nrendo.2017.122
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020). Benefits and risks of bariatric surgery in adults: A review. JAMA, 324(9), 879–887. https://doi.org/10.1001/jama.2020.12567
Kushner, R. F., Calanna, S., Davies, M., et al. (2022). Clinical implications of obesity pharmacotherapy: A review. Obesity, 30(3), 554–567. https://doi.org/10.1002/oby.23387
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., et al. (2017). Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. The New England Journal of Medicine, 376(7), 641–651. https://doi.org/10.1056/NEJMoa1600869
Wiggins, T., Guidozzi, N., Welbourn, R., Ahmed, A. R., & Markar, S. R. (2020). Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: A systematic review and meta-analysis. PLOS Medicine, 17(7), e1003206. https://doi.org/10.1371/journal.pmed.1003206
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., et al. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776–785. https://doi.org/10.1016/S2213-8587(19)30249-9
Zheng, S. L., Roddick, A. J., Aghar-Jaffar, R., Shun-Shin, M. J., Francis, D., Oliver, N., Meeran, K. (2018). Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: A systematic review and meta-analysis. JAMA, 319(15), 1580–1591. https://doi.org/10.1001/jama.2018.3024
Al-Dohayan, D. A., Qamhiah, D. F., Abukhalaf, A. A., Alomar, A. A., Almutairi, F. J., Alsalame, N. M., & Alasbali, M. M. (2021). Cost effectiveness of bariatric surgery in patients with obesity related comorbidities: A retrospective study. Journal of Family Medicine and Primary Care, 10(12), 4418–4422. https://doi.org/10.4103/jfmpc.jfmpc_877_21
Hu, Y., Zheng, S. L., Ye, X. L., Shi, J. N., Zheng, X. W., Pan, H. S., et al. (2022). Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. Annals of Translational Medicine, 10(3), 152. https://doi.org/10.21037/atm-22-200
Mechanick, J. I., Apovian, C., Brethauer, S., Garvey, W. T., Joffe, A. M., Kim, J., et al. (2020). Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity, 28(4), O1–O58. https://doi.org/10.1002/oby.22719
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., Amiel, S. A., Kaplan, L. M., Taroncher-Oldenburg, G., & Cummings, D. E.; Delegates of the 2nd Diabetes Surgery Summit. (2016). Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care, 39(6), 861–877. https://doi.org/10.2337/dc16-0236
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020). Benefits and risks of bariatric surgery in adults: A review. JAMA, 324(9), 879–887. https://doi.org/10.1001/jama.2020.12567
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F.; STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., Amiel, S. A., Kaplan, L. M., Taroncher-Oldenburg, G., & Cummings, D. E.; Delegates of the 2nd Diabetes Surgery Summit. (2016). Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care, 39(6), 861–877. https://doi.org/10.2337/dc16-0236
Arterburn, D. E., Telem, D. A., Kushner, R. F., & Courcoulas, A. P. (2020). Benefits and risks of bariatric surgery in adults: A review. JAMA, 324(9), 879–887. https://doi.org/10.1001/jama.2020.12567
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F.; STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Khera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., Amiel, S. A., Kaplan, L. M., Taroncher-Oldenburg, G., & Cummings, D. E.; Delegates of the 2nd Diabetes Surgery Summit. (2016). Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care, 39(6), 861–877. https://doi.org/10.2337/dc16-0236
Luig, T., Anderson, R., Sharma, A. M., & Campbell Scherer, D. L. (2018). Personalizing obesity assessment and care planning in primary care: Patient experience and outcomes in everyday life and health. Clinical Obesity, 8(6), 411–423. https://doi.org/10.1111/cob.1228
Views:
29
Downloads:
12
Copyright (c) 2025 Piotr Bartnik, Jan Palmi, Elżbieta Bebrysz, Karolina Dębek-Kalinowska, Jarosław Baran, Ida Dunder, Magdalena Koss, Mateusz Biszewski, Aleksandra Drabik, Weronika Ziomek
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
